Background: Peripheral T-cell lymphomas (PTCLs) are rare and heterogeneous diseases with dismal outcome when treated with chemotherapy alone. Because allogeneic stem-cell transplantation (allo-SCT) can cure relapse/refractory patients, we hypothesized that upfront allo-SCT may provide a better outcome. Therefore, all patients that presented with advanced PTCL in our institution at diagnosis were scheduled to undergo upfront allo-SCT after induction chemotherapy.
introduction Peripheral T-cell lymphomas (PTCLs) are rare and heterogeneous diseases that represent around 10%-15% of nonHodgkin's lymphoma (NHL) in adults [1] . No standard of care was established but cyclophosphamide, prednisone, vincristine, hydroxy doxorubicin (CHOP) remains the most frequently used regimen despite very unsatisfactory results. Modest therapeutic progresses have developed during the last several decades. Intensive consolidation therapy such as autologous stem-cell transplantation (auto-SCT) has been investigated. Studies show that upfront auto-SCT can provide good disease control, but only for patients who reach at least a partial response (PR) after induction chemotherapy. It still remains unclear whether auto-SCT is superior to CHOP.
Allogeneic stem-cell transplantation (allo-SCT) is usually carried out in relapse patients. The SFGM-TC group showed that allo-SCT can cure some relapsed/refractory patients [2] .
Other retrospective studies reached similar conclusions [3] [4] [5] . However, few refractory/relapsed PTCLs patients reach complete remission (CR) or PR after salvage therapy, and thus, most relapsed/refractory patients cannot proceed to allo-SCT. Toxicity-related mortality (TRM) of allo-SCT is also a limitation but the use of nonmyeloablative conditioning regimens has changed this paradigm.
Considering that conventional chemotherapy is not a satisfactory treatment of PTCLs and that allo-SCT can cure relapsed/refractory patients, we postulated that better results could be achieved if allo-SCT was carried out earlier in the course of the disease. Therefore, the Hematology Department of Nantes Medical University (Nantes, France) initiated a predefined treatment algorithm including upfront allo-SCT for untreated patients with nonlocalized PTCLs.
patients and methods study design, patient selection and response assessment
Our aim was to assess the feasibility of upfront allo-SCT in patients presenting with nonlocalized PTCL at diagnosis. All patients (18-70 years) with untreated PTCLs (stage >I) that were referred to our Department were systematically scheduled to receive induction chemotherapy followed by upfront allo-SCT. Patients were required to be in response before allo-SCT. The program started in November 2004 and ended in 2012. As it was an observational retrospective study, according to the French legislation (articles L. 1121-1 paragraph 1 and R1121-2, Public Health Code), neither informed consent nor approval of the ethics committee was needed to use data for nontransplanted patients. All transplanted patients signed informed consent and have been reported to the EBMT database.
All PTCL entities classified according to the 2008 WHO classification were eligible, except ALK-positive anaplastic large cell lymphoma (ALCL) and limited cutaneous T-cell lymphomas. Patients that were HIV positive or with major co-morbidities not related to lymphoma at the time of diagnosis were excluded. All cases were diagnosed by local hematopathologists (A.M. and C.B. are experts for the LYSA group).
Disease characteristics at diagnosis were assessed using standard practices. No induction chemotherapy regimen was recommended, but all patients received CHOP. After induction chemotherapy, responder patients with an human leukocyte antigen (HLA)-matched donor proceeded to allo-SCT. The search for an HLA-matched donor began at the time of diagnosis. All donor sources [HLA-matched related or unrelated donor or cord blood units (CBU)] were authorized, and the type of allo-SCT, myeloablative or reduced intensity conditioning (RIC), was adapted to the local practice at the time allo-SCT was carried out (see Supplementary Material S1, available at Annals of Oncology online).
Response [CR, PR, stable disease (SD) or progressive disease (PD)] was defined according to Cheson 99 criteria [6] . Patients' response was assessed after induction chemotherapy, before allo-SCT, at 100 days (D100) and every 3 months during the first year and then every 6 months after in subsequent years. All patients were followed in our department. Outcomes were updated in January 2014. Results are presented on an 'intention-to-transplant' (ITT) basis.
statistical methods
Progression-free survival (PFS) was calculated from the time of diagnosis to the first event (relapse, progression or death from any cause or last followup). Overall survival (OS) was calculated from the time of diagnosis to death or last follow-up. PFS and OS were estimated using the Kaplan-Meier method, and the differences were assessed by the log-rank test. TRM was calculated from time of allo-SCT to death attributed to complications of the allograft. All P values were two-sided and P < 0.05 was considered statistically significant. Data were computed using R software (R Development Core Team, 2014 Table 1 . Forty-nine patients with all inclusion criteria were scheduled to undergo upfront allo-SCT. All patients received CHOP and median number of chemotherapy cycles was 5 (range, 2-8) for transplanted patients and 7 (range, 2-8) for patients that did not undergo transplant. Six patients underwent auto-SCT. Upfront auto-SCT was not part of the initial treatment plan, but the investigators made the medical decision to proceed to auto-SCT, as there was too long of a delay between the end of induction chemotherapy and the availability of an HLA-matched (n = 3) or there was an insufficient response after induction chemotherapy alone (n = 3).
After induction chemotherapy (including auto-SCT), 17 patients reached CR, 21 patients reached PR and 11 patient' disease progressed. Because of an insufficient response, 18 patients received salvage chemotherapy (high-dose cytarabine in 8 cases; pentostatin in 4 cases and other in 6 cases). After salvage chemotherapy, two patients reached CR and eight reached PR.
treatment after induction chemotherapy
An HLA-matched donor was found for 42 patients. Twentynine patients (60%) proceeded to upfront allo-SCT. For the purpose of the present analysis, patients were separated into three groups: group A (n = 29) includes patients with an HLAmatched donor who proceeded to allo-SCT; group B (n = 13) includes patients with an HLA-matched donor who did not proceed to allo-SCT for any medical reason or who refused allo-SCT; and group C (n = 7) includes patients without an HLAmatched donor (see Table 2 ).
GROUP A (n = 29). Before allo-SCT, 22 patients received CHOP alone, while the 7 remaining patients had an insufficient response and received a second chemotherapy treatment. In addition, there were 3 cases of auto-SCT. Before allo-SCT, 12 cases were in first CR and 17 cases were in first PR. The median time from diagnosis to allo-SCT was 6.5 months (range, 2.4-10.4 months). Twenty-four patients proceeded to nonmyeloablative allo-SCT while five patients underwent myeloablative allo-SCT.
GROUP B (n = 13). We did not proceed to upfront allo-SCT for the following reasons: disease progression (n = 8), unfit patient (n = 3), refusal in one case and presence of a pulmonary carcinoma in one case.
GROUP C (n = 7). Only three patients had at least reached PR after induction chemotherapy. The median follow-up (mFU) was 2.5 years (range, 0.3-9.5 years) for the entire cohort (n = 49) and 4.8 years (range, 3-9.5 years) for living patients (n = 27). OS and PFS curves for all patients are shown in Figure 1 . One-and 2-year PFS rates calculated from diagnosis were 53% [95% confidence interval (CI) 41-69] and 51% (95% CI 39-67), respectively. One-and 2-year OS rates were 59% (95% CI 47-75) and 55% (95% CI 43-71), respectively. The patients' outcome according to histology subtypes was as follows: 2-year PFS and OS for patients with peripheral T-cell lymphoma not-otherwise specified (n = 33) were 42.4% (95% CI 28.5-63.1) and 48.5% (95% CI 34.1-68.9), respectively; 100% PTCL-NOS, peripheral T-cell lymphoma not-otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; CR, complete remission, PR, partial remission; auto-SCT, autologous stem-cell transplantation.
and 100%, respectively, for patients with angioimmunoblastic T-cell lymphoma (n = 4; all in group A); 57.1% (95% CI 30.1-100) and 57.1% (95% CI 30.1-100), respectively, for patients with ALCL (n = 7). For patients with other histology subtypes (n = 5), the 2-year PFS and OS were 60% (95% CI 29.3-100) and 60% (95% CI 29.3-100), respectively. OS and PFS according to groups (A, B and C) are shown in Figure 1 .
No patients who underwent allo-SCT experienced grade III-IV acute graft versus host disease (GVHD). Two patients had extensive chronic GVHD (cGVHD) and six patients had limited cGVHD. Two patients died from toxicity related to allo-SCT (one septic shock and one pulmonary fibrosis). Twenty-six patients were still alive at D100 (15 in CR, 7 in PR and 4 in PD). The 1-and 2-year PFS from time of allo-SCT (mFU = 32.2 months) were both 65.5%; the 1-and 2-year OS were 76% (95% CI 62-93) and 72.5% (95% CI 58-91), respectively. Eight patients that received allo-SCT (including two patients in CR at time of allo-SCT) died. The causes of death were disease progression after transplantation in six cases and toxicity in two cases (aspergillus and pulmonary fibrosis). Other nonfatal infections were pulmonary aspergillus (n = 1), cytomegalovirus (CMV) (n = 3) and/or Ebstein Barr virus (EBV) (n = 2) reactivation, BK virus cystitis (n = 1). Thus, the TRM at 1 year was 8.2% (95% CI 0-18.5). At time of relapse, two patients received donor lymphocytes infusions (DLIs). One did not respond and the other reached PR. Eighteen patients presented at diagnosis with IPI >1. Among them, 13 did not relapse after allo-SCT and are still in CR. In group B, the PFS and OS were very short; the 3-year OS was 30.8% (95% CI 13.6-69.5). Among the 11 patients with IPI >1, only one remained in CR.
Only two of seven patients from group C were alive, including one patient with IPI >1. The causes of death were PTCL (n = 4) and encephalitis (n = 1). The 2-year PFS and OS were both 28.6% (95% CI 8.86% to 92.2%). The outcomes were similar for patients in groups B and C.
statistical analysis
See supplementary Material S2, available at Annals of Oncology online. Patients of group A had a better outcome than patients in groups B and C (A versus B + C, P = 0.0008 for OS and P = 0.0048 for PFS).
There was no difference in PFS or OS among group A patients when we compared age, donor source, histology subtypes or nature of conditioning regimen. Only the disease status at time of transplantation showed a statistical significant value correlating to both OS and PFS (see Figure 2A) . Notably, there was also a trend toward a better OS for transplanted patients who experienced cGVH compared with those who did not ( Figure 2B ).
discussion
This study shows that despite identification of an HLA-matched donor in nearly 80% of patients, only 60% proceeded to upfront allo-SCT and TRM was low for patients receiving allo-SCT.
The SFGM-TC and other studies reported a TRM of 28% [5, [7] [8] [9] . These results suggested that allo-SCT was too toxic to be carried out upfront. Herein, the TRM is lower and close to Corradini's report including only RIC-allo [3] . Corradini et al. also reported a phase II trial that included untreated PTCL patients that underwent allo-SCT and only 3 of 23 patients died from allo-SCT-related toxicity [10] . Robles et al. also reported that allo-SCT at time of first response does not result in high TRM [4] . The low TRM may be because (i) patients had not received high doses of chemotherapy before allo-SCT, (ii) allo-SCT was carried out upfront and (iii) patients underwent a nonmyeloablative allo-SCT procedure. Indeed, TRM in the modern era is not likely an issue. Thus, a key outstanding question is whether upfront allo-SCT provides better PFS and/or OS than other upfront standard therapeutic options. CHOP-like regimens have been evaluated in several studies [11] [12] [13] [14] . The 5-year OS was never higher than 50%. Herein, only 5 of 20 untransplanted patients reached prolonged CR without relapse. Unfortunately, routine biologic examinations are unable to identify highly chemo-sensitive patients. The combination of anthracycline-based chemotherapy regimen with other drugs did not increase its effectiveness [10, 15, 16] . Therefore, upfront standard chemotherapy alone cannot be the only acceptable option for fit PTCL patients. The use of upfront auto-SCT has been studied. D'Amore et al. showed that the 5-year OS and PFS were 51% and 44%, respectively [17] . Interestingly, outcome of auto-SCT patients is very encouraging (5-year OS of 61%). In contrast, Reimer previously reported poor results for patients in CR after auto-SCT; the 3-year OS and PFS were 48% and 36%, respectively [18] . To date, no side-by-side comparison of chemotherapy alone versus chemotherapy plus auto-SCT has been carried out. Few studies have addressed allo-SCT in PTCLs [2, 3, 9, 19, 20] . The outcome of relapsed/refractory patients after allo-SCT varies between studies: the 3-year PFS was 75% in Corradini's report (n = 17) [3] , 33% by Feyer et al. [8] , 53% after 5 years in Le Gouill's report [2] or 31% after 3 years in Hamadani's report [9] . Despite these discrepancies, all reports concluded that (i) allo-SCT provides long-term disease control even for chemo-refractory patients, (ii) the disease status at the time of allo-SCT is a major prognostic marker and (iii) the graft versus T-cell lymphoma effect has a favorable impact. To our knowledge, our present study and Robles's and Corradini's studies are the only published reports of upfront allo-SCT in PTCLs [9, 10] . Herein, the 2-year PFS of allo-SCT patients was 65.5%, and the 4-year PFS was 69% in the Italian study [10] . In Corradini's study, the authors failed to show any difference (OS or PFS) between auto-SCT versus allo-SCT but, as mentioned by the authors, this study was not designed to determine this benefit. Similarly, our work cannot be considered to be a comparison between allo-SCT versus non-allo-SCT. Indeed, primary chemo-refractory patients are all in groups B and C and not in A. However, outcome after upfront allo-SCT for patients presenting with IPI >1 is very encouraging and better to what has been reported after upfront auto-SCT so far. Two patients also received DLIs at time of relapse and both responded. These findings provide a strong rationale to offer upfront allo-SCT for IPI >1 patients. Result of a phase III trial comparing auto-SCT versus allo-SCT in PTCLs (Eudrac 2007-001052-39) is highly warranted.
In PTCLs, the high percentage of primary chemo-resistance patients remains a major issue. Interestingly, long-term disease control after Brentuximab vedotin (BV) alone has been reported in relapsed ALCLs [21, 22] . BV can also be used as a bridge to allo-SCT [23] . These results are the basis for an ongoing trial (NCT01777152) comparing CHOP versus BV plus CHOP. However, CD30 expression levels vary among PTCLs [24] . The threshold of CD30 positivity of tumor cells required to respond to BV is also unknown. A phase II trial showed that single-agent Romidepsin, a histone deacetylase inhibitor, contributes to 15% of CR in relapsed/refractory PTCL [25] . An international phase III trial is currently comparing CHOP versus CHOP plus Romidepsin in untreated PTCL (NCT01796002). Other new drugs are currently being investigated. Results of these trials may change PTCL patient outcomes [26] . Advances in PTCL treatment will also come from a better understanding of PTCL biology [27, 28] .
In conclusion, our work demonstrates that upfront allo-SCT of PTCLs is feasible with low TRM, and that long-term disease control after allo-SCT is achievable for more than half of patients. Primary chemo-resistance remains an issue in PTCLs, 
